U.K. authority slaps Merck for Januvia promos; Abbott cuts formula prices amid Chinese probe;

@FiercePharma: Investors hiss at Pharmstandard spinoff engineering. Plans to buy out investors who oppose OTC deal--at a discount. More | Follow @FiercePharma

 @CarlyHFierce: Alleged Botox marketing strategy in China named for Russian sniper Vasily Zaytsev - anyone seen Enemy at the Gates? More (sub. req.) | Follow @CarlyHFierce

> Merck's ($MRK) unit in the U.K. was censured by the Prescription Medicines Code of Practice Authority for infringing its marketing code with its Januvia promotions. Report

> Amid a pricing probe in China, Abbott Laboratories ($ABT) cut the prices on its infant formula sold there by up to 12%. Report

> Chile's CFR Pharmaceuticals says that, after buying South Africa's Adcock Ingram, it would list the combined company's shares on the Johannesburg Stock Exchange. Report

> The General Court of the European Union tossed out a 2011 decision to deny marketing approval to Laboratoires CTRS' orphan drug Orphacol. Report

> Novartis ($NVS) tapped Insight Public Affairs to handle its corporate and brand communications with the government, to promote the pharma industry's role in the U.K. economy. Report

> The market for dry-eye treatments is growing as more people develop the syndrome, partly because of increased use of computers, tablets and smartphones. Report

Medical Device News

@FierceMedDev: New special report: A look at 2013's hot M&A start. Feature | Follow @FierceMedDev

 @MarkHFierce: It's not easy for Dx outfits to win Medicare coverage in today's market, but Crescendo did. Story | Follow @MarkHFierce

@DamianFierce: Are Intuitive's weak da Vinci sales a hiccup or an omen? Shares slipped 15% overnight. News | Follow @DamianFierce

> Diagnostic device detects bladder cancer through urine odor. Article

> Tyrx gains FDA clearance for dissolvable antibacterial envelope. Story

> Denmark wants EU ban on chemical used in device manufacturing. More

Biotech News

@FierceBiotech: 'Fraud' found at China site for key study of Pfizer and Bristol's Eliquis. Report | Follow @FierceBiotech

 @JohnCFierce: Amgen commits $50M-plus in 3-way deal to expand cardiovascular drug pipeline. Article | Follow @JohnCFierce

@RyanMFierce: Expert exposes "highly questionable" data from biotech Cardio3 after IPO. ICYMI yesterday | Follow @RyanMFierce

> UniQure snags $58M in collaboration cash plus equity. Item

> Forma enlists expert partners to create a portfolio of virtual cancer biotechs. Report

> GlaxoSmithKline teams with Immunocore on next-gen cancer immunotherapies. News

Pharma Manufacturing News

 @EricPFierce: I'm looking for pharma folks interested in being part of a webinar on how their companies are using marketing apps to talk with clients. Let me know. | Follow @EricPFierce

> Nikkei: Teva to double manufacturing capacity in Japan. More

> Wockhardt faces 2nd import alert. Report

> Hikma New Jersey plant back in production. Article

> Fresenius gets 2nd warning letter in 18 months. Story

Biotech Research News

 @EmilyMFierce: Ohio-based startup Biosortia is tapping into nature to fill early drug-discovery void. Editor's corner | Follow @EmilyMFierce

> U.K. launches large-scale genomics project. More

> Immune modulation could explain how experimental Alzheimer's therapy works. Item

> More positive preclinical results for Inovio's H7N9 vaccine. Story

> New research could help cut cardiovascular risks associated with arthritis drugs. Article

And Finally... Who needs a pill when they have a pencil? Drawing pictures of comfort food can ease cravings, study finds. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.